Myelodysplastic Syndromes
1,001
129
188
492
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
207 trials with published results (21%)
Research Maturity
492 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.3%
153 terminated out of 1001 trials
76.3%
-10.3% vs benchmark
8%
81 trials in Phase 3/4
42%
207 of 492 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 492 completed trials
Clinical Trials (1001)
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
A Study of BGB-11417 in Participants With Myeloid Malignancies